BioAnalytics Group Partners with Prescient to Develop Cardiovascular Diagnostics, Therapeutics | GenomeWeb
NEW YORK (GenomeWeb News) - The BioAnalytics Group said last week that it is collaborating with Prescient Medical to develop heart attack prevention and treatment technologies.
Under the agreement, the BioAnalytics Group will use its Model Based Assay biosimulation methodologies to help Prescient calibrate and optimize a Raman Spectroscopy-based diagnostic system to characterize vulnerable plaque.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.